Medtronic Plc (NYSE:MDT) on Tuesday reported third-quarter 2026 results, with sales hitting $9.02 billion, surpassing the consensus estimate of $8.91 billion. This marks an 8.7% increase year-over-year, with organic growth of 6%.
Adjusted earnings of $1.36 per share also beat expectations of $1.33.
Segment Performance
Cardiovascular Portfolio revenue of $3.457 billion, an increase of 13.8% as reported and 10.6% organic, with high-teens increase in Cardiac Rhythm & Heart Failure, low-single digit increase in Structural Heart & Aortic, and mid-single digit increase in Coronary & Peripheral Vascular, all on an organic basis.
Neuroscience Portfolio revenue of $2.558 billion, an increase of 4.1% reported and 2.5% organic, with a mid-single digit increase in Neuromodulation, a mid-single digit increase in Cranial & Spinal Technologies, and flat results in Specialty Therapies, all on an organic basis
Medical …